Phase I study with the DNA sequence-specific agent adozelesin

Anti-Cancer Drugs

Volumn 8, Issue 6, 1997, Pages 588-596

  Burris, Howard A ^a,b,c   Dieras, Veronique C ^b,d   Tunca, Mehmet ^b,e   Earhart, Robert H ^f   Eckardt, John R ^a,b   Rodriguez, Gladys I ^a,b   Shaffer, Donald S ^c   Fields, Suzanne M ^a,b   Campbell, Elizabeth ^b   Schaaf, Larry ^f   Kasunic, Dorothy ^f   Von Hoff, Daniel D ^a,b,g  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d INSTITUT CURIE   (France)

^e DOKUZ EYLUL UNIVERSITY   (Turkey)

^f PFIZER INC   (United States)

^g CTRC Institute for Drug Development   (United States)

Author keywords

Adozelesin alkylating agents; DNA minor groove binders; Phase I

Indexed keywords

ADOZELESIN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD; CYCLOHEXANECARBOXYLIC ACIDS; CYCLOHEXENES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERGLYCEMIA; INDOLES; INFUSIONS, INTRAVENOUS; LIVER; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; TREATMENT OUTCOME;

EID: 8544261171     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199707000-00006     Document Type: Article

References (32)

1. Wierenga W, Bhuyan BK, Kelly RC, et al. Antitumor activity and biochemistry of novel analogs of the antibiotic, CC-1065. Adv Enzyme Reg 1986; 25: 141-55.
2. Li LH, Wallace TL, DeKoning TF, et al. Structure and activity relationship of several novel CC-1065 analogs. Invest New Drugs 1987; 5: 329-37.
3. Martin DG, Chidester CG, Duchamp DJ, et al. Structure of CC-1065 (NSC-298223), a new antitumor antibiotic. J Antibiot 1980; 33: 902-3.
4. Weiland KL, Dooley TP. In vitro and in vivo DNA binding by the CC-1065 analogue U-73975. Biochemistry 1991; 30: 7559-65.
5. Wierenga W. Improving on nature: a structure-activity approach to DNA-interactive antitumor agents. In Proc 6th NCI-EORTC Symp. on New Drugs in Cancer Therapy, Amsterdam 1989; A016 (abstr).
6. Hanka LJ, Dietz A, Gerpheide SA, et al. CC-1065 (NSC 298223), a new antitumor antibiotic: production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism. J Antibiot 1978; 31: 1211-7.
7. Chidester CG, Krueger WC, Mizsak SA, et al. The structure of CC-1065, a potent antitumor agent, and its binding to DNA. J Am Chem Soc 1981; 103: 7629-35.
8. Swenson DH, Li LH, Hurley LH, et al. Mechanism of interaction of CC-1065 (NSC 298223) with DNA. Cancer Res 1982; 42: 2821-8.
9. Reynolds VL, Molineux IJ, Kaplan DJ, et al. Reaction of the antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity. J Biochemistry 1985; 24: 6228-37.
10. Li LH, Swenson DH, Schpok SLF, et al. CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA. Cancer Res 1982; 42: 999-1004.
11. Bhuyan BK, Newell KA, Crampton SL, et al. CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival. Cancer Res 1982; 42: 3532-7.
12. McGovren JP, Clarke GL, Pratt EA, et al. Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065. J Antibiot 1984; 37: 63-70.
13. Kelly RC, Gebhard I, Wicnienski N, et al. Coupling of cyclopropylpyrroloindole (CPI) derivatives. The preparation of CC-1065 and analogues. J Am Chem Soc 1987; 109: 6837-8.
14. Warpehoski MA. CC-1065 analogs: Therapeutic potential of a sequence specific drug-DNA reaction. Proc Am Ass Cancer Res 1989; 30: 668-9.
15. Petzold GL, McGovren JP, Smith KS, et al. Correlation of CHO cell lethality to drug uptake and DNA binding for three cyclopropylpyrroloindole (CPI) analogs. Proc Am Ass Cancer Res 1991; 32: 333 (A1974).
16. Warpehoski MA, Harper DE, Mitchell MA, et al. Reversibility of the covalent reaction of CC-1065 and analogues with DNA. Biochemistry 1992; 31: 2502-8.
17. Wang Y, Lown JW. Potent CC-1065 analogues with different DNA-sequence-specific binding properties. Proc Am Ass Cancer Res 1993; 34: 268 (A1593).
18. Li LH, Kelly RC, Warpehoski MA, et al. Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065. Invest New Drugs 1991; 9: 137-48.
19. Lee CS, Gibson NW. DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues, U-73,975 and U-77,779. Cancer Res 1991; 51: 6586-91.
20. Lee CS, Gibson NW. Cytotoxicity and DNA damage in human colon carcinoma cells by CC-1065 analogs, U-73,975 and U-77,779. Proc Am Ass Cancer Res 1991: 32: 320 (A1901).
21. Nguyen HN, Sevin BU, Averette H, et al. In vitro evaluation of a novel chemotherapeutic agent, adozelesin, in gynecologic-cancer cell lines. Cancer Chemother Pharmacol 1992; 30: 37-42.
22. Bhuyan BK, Smoth KS, Adams EG, et al. Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects. Cancer Chemother Pharmacol 1992; 30: 348-54.
23. Bhuyan BK, Smith KS, Adams EG, et al. Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells. Cancer Res 1992; 52: 5687-92.
24. Alberts D, Einspahr J, Sipes IG. In vitro cytotoxicity of a novel DNA minor groove binding anticancer agent (U-73, 975) against doxorubicin-sensitive and resistant human tumor cell lines. Proc Am Ass Cancer Res 1989; 30: 492 (A1957).
25. Hightower RD, Sevin BU, Perras JP, et al. Comparison of U-73, 975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with the ATP-chemosensitivity assay. Gynecol Oncol 1992; 47: 186-90.
26. Ratain MJ, Von Hoff DD, Alberts DS, et al. Phase I trial program for adozelesin (U-73, 975). Ann Oncol 1992; 3 (suppl 1): 160 (A405).
27. Burris H, Earhart R, Kuhn J, et al. A phase I trial of adozelesin, a novel DNA sequence-specific alkylating agent. Proc Am Ass Cancer Res 1992; 33: 520 (A3106).
28. Burris H, Earhart R, Kuhn J, et al. A phase I clinical and pharmacokinetic trial of adozelesin. Ann Oncol 1992; 3 (suppl 1): 132 (A291).
29. Hersh MR, Lim W, Kuhn JG, et al. Electrocardiographic monitoring of patients receiving phase I cancer chemotherapy. Cancer Treat Rep 1986; 70: 349-52.
30. Mayernick D, Stevenson J, Neidhart J. Acute cardiac arrhythmias with phase I and II agents. Proc Am Soc Clin Oncol 1982; 1: 14 (C-53).
31. Shamdas GJ, Alberts DS, Modiano M, et al. Phase I study of adozelesin (U-73.975) in patients with solid tumors. Anti-Cancer Drugs 1994; 5: 10-14.
32. Fleming GF, Ratain MJ, O'Brien SM, et al. Phase I study of adozelesin administered by 24-hour continuous infusion. J Natl Cancer Inst 1994; 86: 368-72.